CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 15 enrolled
Drug / intervention
Pembrolizumab +1 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03299088
NCT03299088Phase 1Completed
CompareCT.gov

A Phase Ib Trial of Pembrolizumab (MK-3475) and Trametinib Focused on Advanced KRAS Mutant Non-small Cell Lung Cancer

Jonathan Riess·interventional·Posted Oct 2, 2017·Updated May 21, 2025

In Brief

A Phase 1 clinical trial evaluating Pembrolizumab and Trametinib for KRAS Gene Mutation and 3 related conditions. Completed, enrolled 15 participants across 1 site.

Detailed Summary

This phase Ib trial studies the side effects of pembrolizumab and trametinib in treating patients with non-small cell lung cancer and KRAS gene mutations that has spread to other places in the body. Monoclonal antibodies, such as pembrolizumab, may interfere with the ability of tumor cells to grow and spread. Trametinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving pembrolizumab and trametinib may work better in treating patients with non-small cell lung cancer.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsKRAS Gene Mutation, Metastatic Non-Squamous Non-Small Cell Lung Carcinoma, Recurrent Non-Squamous Non-Small Cell Lung Carcinoma, Stage IV Non-Small Cell Lung Cancer AJCC v7
CountriesUnited States
CollaboratorsMerck Sharp & Dohme LLC, Novartis, National Cancer Institute (NCI)

Timeline

Phase 1CompletedFinished
201820192020202120222023202420252026
First PostedOct 2, 2017
Enrollment StartJun 26, 2018
Primary CompletionJan 28, 2021
Study CompletionJun 25, 2024
TodayJul 2, 2026
Enrollment to primary: 2.6 yearsPosted 8.8 years ago

Interventions

Pembrolizumabbiological

Given IV

Trametinibdrug

Given PO